A Denicoff
Overview
Explore the profile of A Denicoff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
25
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zujewski J, Pai L, Wakefield L, Giusti R, Dorr F, Flanders C, et al.
Breast Cancer Res Treat
. 2000 Jan;
57(3):277-83.
PMID: 10617304
Background: Tamoxifen and fenretinide combination therapy has been shown to be an active treatment regimen in metastatic breast cancer patients. This pilot study sought to determine whether the addition of...
2.
Fisherman J, Cowan K, Noone M, Denicoff A, Berg S, Poplack D, et al.
J Clin Oncol
. 1996 Mar;
14(3):774-82.
PMID: 8622023
Purpose: We conducted a phase I/II trial of concurrently administered 72-hour infusional paclitaxel and doxorubicin in combination with granulocyte colony-stimulating factor (G-CSF) in patients with previously untreated metastatic breast cancer...
3.
OShaughnessy J, Venzon D, Gossard M, Noone M, Denicoff A, Tolcher A, et al.
Blood
. 1995 Oct;
86(8):2913-21.
PMID: 7579383
Cumulative thrombocytopenia is a dose-limiting toxicity of dose-intensive chemotherapy for advanced breast cancer. In this phase I study, we have studied the hematologic toxicity associated with sequential interleukin-3 (IL-3) and...
4.
Kolachana P, Cowan K, Denicoff A, Jones E, Choyke P
J Comput Assist Tomogr
. 1995 Jul;
19(4):592-5.
PMID: 7622690
Objective: The goal of this study was to quantify changes in uterine volume during and after chemotherapy for breast cancer. Materials And Methods: Fifty-eight patients (mean age 42 years) with...
5.
Bates S, Meadows B, Goldspiel B, Denicoff A, Le T, Tucker E, et al.
Cancer Chemother Pharmacol
. 1995 Jan;
35(6):457-63.
PMID: 7882454
Increasing evidence suggests that P-glycoprotein (Pgp) expression can mediate drug resistance in refractory breast cancer. We studied 33 patients with refractory breast cancer enrolled in a pilot study of oral...